{"id":741529,"date":"2023-03-21T08:33:16","date_gmt":"2023-03-21T12:33:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/"},"modified":"2023-03-21T08:33:16","modified_gmt":"2023-03-21T12:33:16","slug":"nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/","title":{"rendered":"NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra"},"content":{"rendered":"

<\/p>\n

NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra<\/b><\/p>\n

Next Generation Device Configured with Multiple Frequencies to Enhance Product Performance and Effectiveness<\/b><\/i><\/p>\n

ELMSFORD, N.Y.–(BUSINESS WIRE<\/a>)–NanoVibronix, Inc<\/a>., (NASDAQ: NAOV) (the \u201cCompany\u201d), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (\u201cSAW\u201d) technology, today announced it has filed a new provisional patent application with the United States Patent and Trademark Office (\u201cUSPTO\u201d) entitled \u201cMultiple Frequency Surface Acoustic Waves for Internal Medical Device\u201d (the “Patent Application”) related to its UroShield.\n<\/p>\n

\nThe Patent Application covers a recently developed enhancement to the UroShield product, UroShield \u201cUltra\u201d, which incorporates improvements to the Company\u2019s original UroShield. The next generation UroShield Ultra includes modified housing that is designed to improve catheter coupling and incorporates multiple actuators that work in sequence to discourage bacterial docking by delivering SAWs at multiple frequencies directly to indwelling catheters.\n<\/p>\n

\n\u201cUroShield is, to our knowledge, the only proven, effective solution for the prevention of Catheter Associated Urinary Tract Infections (\u201cCAUTI\u201d), the single highest source of hospital acquired infections,\u201d stated Brian Murphy, Chief Executive Officer of NanoVibronix. \u201cThis new filing expands our portfolio of intellectual property assets and reinforces our competitive position. UroShield has been proven to be instrumental in improving outcomes for hospital patients suffering from CAUTI. We are continually seeking opportunities to improve our products and by employing cutting edge technology.\u201d\n<\/p>\n

About NanoVibronix, Inc.<\/b><\/p>\n

\nNanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company\u2019s primary products include PainShield\u00ae, UroShield\u00ae and WoundShield\u00ae, all of which are portable devices suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com<\/a>.\n<\/p>\n

Forward-looking Statements<\/b><\/p>\n

\nThis press release contains \u201cforward-looking statements.\u201d Such statements may be preceded by the words \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cprojects,\u201d \u201cpredicts,\u201d \u201cestimates,\u201d \u201caims,\u201d \u201cbelieves,\u201d \u201chopes,\u201d \u201cpotential\u201d or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company\u2019s control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) market acceptance of our existing and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results; (iii) inability to secure regulatory approvals for the sale of our products; (iv) intense competition in the medical device industry from much larger, multinational companies; (v) product liability claims; (vi) product malfunctions; (vii) our limited manufacturing capabilities and reliance on subcontractor assistance; (viii) insufficient or inadequate reimbursements by governmental and\/or other third party payers for our products; (ix) our ability to successfully obtain and maintain intellectual property protection covering our products; (x) legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xi) our reliance on single suppliers for certain product components; (xii) the need to raise additional capital to meet our future business requirements and obligations, given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiii) our conducting business in foreign jurisdictions exposing us to additional challenges, such as, e.g., foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and political and\/or economic instabilities in specific jurisdictions; and (xiv) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company\u2019s filings with the Securities and Exchange Commission (SEC), including the Company\u2019s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC\u2019s web site at: http:\/\/www.sec.gov<\/a>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230321005237\/en\/<\/a><\/span><\/p>\n

Investor Contacts:
\n<\/b>
Brett Maas, Managing Principal, Hayden IR, LLC
\n
brett@haydenir.com
\n<\/a>
(646) 536-7331\n<\/p>\n

KEYWORDS:<\/b> United States North America New York<\/p>\n

INDUSTRY KEYWORDS:<\/b> Professional Services Patent Law Medical Devices Health Health Technology General Health<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra Next Generation Device Configured with Multiple Frequencies to Enhance Product Performance and Effectiveness ELMSFORD, N.Y.–(BUSINESS WIRE)–NanoVibronix, Inc., (NASDAQ: NAOV) (the \u201cCompany\u201d), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (\u201cSAW\u201d) technology, today announced it has filed a new provisional patent application with the United States Patent and Trademark Office (\u201cUSPTO\u201d) entitled \u201cMultiple Frequency Surface Acoustic Waves for Internal Medical Device\u201d (the “Patent Application”) related to its UroShield. The Patent Application covers a recently developed enhancement to the UroShield product, UroShield \u201cUltra\u201d, which incorporates improvements to the Company\u2019s original UroShield. The next generation UroShield Ultra includes modified housing that is designed to improve catheter coupling … <\/p>\n

Continue reading “NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-741529","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra Next Generation Device Configured with Multiple Frequencies to Enhance Product Performance and Effectiveness ELMSFORD, N.Y.–(BUSINESS WIRE)–NanoVibronix, Inc., (NASDAQ: NAOV) (the \u201cCompany\u201d), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (\u201cSAW\u201d) technology, today announced it has filed a new provisional patent application with the United States Patent and Trademark Office (\u201cUSPTO\u201d) entitled \u201cMultiple Frequency Surface Acoustic Waves for Internal Medical Device\u201d (the “Patent Application”) related to its UroShield. The Patent Application covers a recently developed enhancement to the UroShield product, UroShield \u201cUltra\u201d, which incorporates improvements to the Company\u2019s original UroShield. The next generation UroShield Ultra includes modified housing that is designed to improve catheter coupling … Continue reading "NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-21T12:33:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230321005237r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra\",\"datePublished\":\"2023-03-21T12:33:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\\\/\"},\"wordCount\":815,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230321005237r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\\\/\",\"name\":\"NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230321005237r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-03-21T12:33:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230321005237r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230321005237r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/","og_locale":"en_US","og_type":"article","og_title":"NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra - Market Newsdesk","og_description":"NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra Next Generation Device Configured with Multiple Frequencies to Enhance Product Performance and Effectiveness ELMSFORD, N.Y.–(BUSINESS WIRE)–NanoVibronix, Inc., (NASDAQ: NAOV) (the \u201cCompany\u201d), a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave (\u201cSAW\u201d) technology, today announced it has filed a new provisional patent application with the United States Patent and Trademark Office (\u201cUSPTO\u201d) entitled \u201cMultiple Frequency Surface Acoustic Waves for Internal Medical Device\u201d (the “Patent Application”) related to its UroShield. The Patent Application covers a recently developed enhancement to the UroShield product, UroShield \u201cUltra\u201d, which incorporates improvements to the Company\u2019s original UroShield. The next generation UroShield Ultra includes modified housing that is designed to improve catheter coupling … Continue reading \"NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-21T12:33:16+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230321005237r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra","datePublished":"2023-03-21T12:33:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/"},"wordCount":815,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230321005237r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/","name":"NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230321005237r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-03-21T12:33:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230321005237r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230321005237r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-files-provisional-u-s-patent-application-for-uroshield-ultra\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NanoVibronix Files Provisional U.S. Patent Application for UroShield Ultra"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/741529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=741529"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/741529\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=741529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=741529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=741529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}